Last reviewed · How we verify
NCT04790955
Effect of Combination Therapy on SCLC After Initial Treatment Failure
trial in Small-cell Lung Cancer in 48 participants. Status unknown.
1 March 2024
Quick facts
| Lead sponsor | First Affiliated Hospital of Harbin Medical University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 48 |
| Start date | 1 March 2021 |
| Primary completion | 1 March 2024 |
| Estimated completion | 1 March 2024 |
Conditions studied
- Small-cell Lung Cancer — all drugs for Small-cell Lung Cancer →
Sponsor
First Affiliated Hospital of Harbin Medical University
Who can join
Adults 18 to 80, any sex, with Small-cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
SCLC patients after initial treatment failure are treated with SBRT and low-dose radiotherapy concurrent with PARP inhibitors + temozolomide +PD-1/PD-L1 inhibitors for two cycles at least, then PARP inhibitors+temozolomide+PD-1/PD-L1 inhibitors two cycles, PD-1/PD-L1 inhibitors maintenance therapy lasted for up to 2 years.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers.
Luo L, Keyomarsi K. · · 2022 · cited 56× · PMID 35435784 · DOI 10.1080/13543784.2022.2067527 -
P53 and Rb Aberrations in Small Cell Lung Cancer (SCLC): From Molecular Mechanisms to Therapeutic Modulation.
Papavassiliou KA, Sofianidi AA, Gogou VA, Anagnostopoulos N, et al · · 2024 · cited 19× · PMID 38473726 · DOI 10.3390/ijms25052479 -
Advances in molecular targeted therapies to increase efficacy of (chemo)radiation therapy.
Viktorsson K, Rieckmann T, Fleischmann M, Diefenhardt M, et al · · 2023 · cited 19× · PMID 37041372 · DOI 10.1007/s00066-023-02064-y
Verify or expand the search:
- PubMed search for NCT04790955
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Small-cell Lung Cancer
Currently open trials in the same condition.
- NCT07155200 — Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial) · Phase 1, PHASE2 · recruiting
- NCT07218146 — A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVAT · Phase 3 · recruiting
- NCT07005128 — A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in Fi · Phase 3 · recruiting
- NCT06424067 — Phase 2 Study of Fingolimod in Lung Cancers · Phase 2 · recruiting
- NCT06957314 — A Study of Hospital-at-Home for People Receiving Tarlatamab · NA · recruiting
Other First Affiliated Hospital of Harbin Medical University trials
Trials by the same sponsor.
- NCT07020195 — QFR-Based Functional SYNTAX Score System in Optimizing Revascularization Strategy for Multivessel Disease · NA · not yet recruiting
- NCT06975592 — Study on the Mechanism of Multi-group Analysis of the Influence of Depression on Common Cardiovascular Diseases · not yet recruiting
- NCT06995456 — Multivariate Analysis and Prediction of Hypertensive Disorder Complicating Pregnancy and Its Related Mechanism · not yet recruiting
- NCT07087093 — Effects of Ketone Esters on Circulating Senescent T Lymphocytes (T Cells) and Inflammation Levels in the Elderly · NA · recruiting
- NCT06565845 — Analysis of Various Treatment Methods of Granulomatous Lobular Mastitis · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04790955 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by First Affiliated Hospital of Harbin Medical University
- Last refreshed: 10 March 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04790955.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing